FOSTER CITY, California: Gilead Sciences Inc is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion.
Gilead in a statement on Monday said it is looking at ways to use remdesivir earlier in the course of disease, including via alternate formulations. The company confirmed in an email that it is researching an inhaled version, but declined further comment.Company executives such as Chief Medical Officer Merdad Parsey and Chief Financial Officer Andrew Dickinson have been doing interviews with Wall Street analysts in recent weeks to discuss the plans, which are in early stages.
The idea is that a nebuliser would make remdesivir more directly available to upper airway and lung tissue as the coronavirus is known to attack the lungs. It would also allow for early treatment of coronavirus patients who are not hospitalised.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: The Straits Times - 🏆 8. / 63 Read more »